- Time:
Artificial Intelligence (AI) and machine learning are transforming the worlds of biotechnology and pharma, particularly in the arena of drug discovery. Leveraging the rise of large datasets and massive compute power, AI appears poised to expedite and, in some cases, reimagine the design of novel and more effective therapeutics, from cell and gene therapy, oncology, neuroscience, and more.
In GEN’s inaugural virtual summit, The State of AI in Drug Discovery, we proudly host an outstanding group of thought-leaders, researchers and AI entrepreneurs across industry and academia to showcase the latest advances, challenges and concerns regarding the deployment of AI in biotech, with particular emphasis on disrupting the drug discovery process. This exciting event brings together founders and executives from many of the most exciting companies powering the AI revolution, including Recursion, 1910 Genetics, Profluent, Terray Therapeutics, Generate:Biomedicines, and more!
Please join us on October 30th for a dynamic program featuring:
- A keynote presentation with Nobel Laureate David Baker, PhD (University of Washington/HHMI)
- A keynote fireside chat with Najat Khan, PhD (Recursion) on growing the AI in drug discovery industry
- From computational platforms to protein design with Ava Amini, PhD (Microsoft Research), Gevorg Grigoryan, PhD (Generate: Biomedicines), Karen Akinsanya, PhD (Schrödinger)
- Foundational models to read and write the language of biology with Ali Madani, PhD (Profluent), Brian Hie, PhD (Arc Institute), and Alex Rives, PhD (EvolutionaryScale)
- Key considerations for AI-based small molecule drug discovery with experts from 1910 Genetics, Terray Therapeutics, insitro, and Insilico Medicine
- AI in drug discovery’s evolving business landscape with Simon Barnett (Dimension), Sabrina Yang, PhD (Empress Therapeutics/Flagship Pioneering) and Colin Hill (Aitia Bio)
- Breakout sessions from our event sponsors
Registration for The State of AI in Drug Discovery is entirely free.
Guest Speakers Include
